Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group.

Details

Language :

English

ISSN :

0732183X

Volume :

26

Issue :

6

Database :

Supplemental Index

Journal :

Journal of Clinical Oncology

Publication Type :

Academic Journal

Accession number :

105862237

Full Text :

https://doi.org/10.1200/JCO.2007.11.9941